Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 9/20 | 0.71 |
| ▸ | PPARA | Q07869 | 9/20 | 0.71 |
| ▸ | PPARD | Q03181 | 7/20 | 0.71 |
| ▸ | PHGDH | O43175 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | NR1H4 | Q96RI1 | 6/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4692410 | 0.83 | PPARG (0.73) | PPARGPPARAPPARDPHGDHNR1H4 | |
| SCHEMBL2808248 | 0.83 | PPARA (1.00) | PPARGPPARAPPARDPHGDH | |
| SCHEMBL2806181 | 0.82 | PPARG (0.75) | PPARGPPARAPPARD | |
| SCHEMBL4694981 | 0.81 | PPARG (0.64) | PPARGPPARAPPARDPHGDH | |
| SCHEMBL4691715 | 0.81 | PPARG (0.60) | PPARGPPARAPPARDPHGDHNR1H4 | |
| SCHEMBL4787025 | 0.80 | PPARA (0.80) | PPARGPPARAPPARDPHGDHMEN1 | |
| SCHEMBL4692771 | 0.78 | PPARG (0.56) | PPARGPPARAPPARDPHGDHALDH1A1 | |
| SCHEMBL2807596 | 0.78 | PPARG (0.76) | PPARGPPARAPPARDPHGDH | |
| SCHEMBL4688939 | 0.77 | PPARA (0.79) | PPARGPPARAPPARD | |
| SCHEMBL4688952 | 0.75 | PPARG (0.65) | PPARGPPARAPPARDPHGDHRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1685113-B1 | SUBSTITUTED PYRAZOLES AS PPAR AGONISTS | SMITHKLINE BEECHAM CORP (US) | 2008-07-30 | — | — | EP | disclosed |
| EP-1685113-B1 | SUBSTITUTED PYRAZOLES AS PPAR AGONISTS | SMITHKLINE BEECHAM CORP (US) | 2008-07-30 | — | — | EP | disclosed |
| US-20080021030-A1 | Substituted Pyrazoles As Ppar Agonists | SMITHKLINE BEECHAM CORPORATION | 2008-01-24 | — | — | US | disclosed |
| US-20080021030-A1 | Substituted Pyrazoles As Ppar Agonists | SMITHKLINE BEECHAM CORPORATION | 2008-01-24 | — | — | US | disclosed |
| US-20080021030-A1 | Substituted Pyrazoles As Ppar Agonists | SMITHKLINE BEECHAM CORPORATION | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021030-A1 | Substituted Pyrazoles As Ppar Agonists | PPARD, PPARA, PPARG | PPARG 3/4885PPARA 2/4885PPARD 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.